Cullen Frost Bankers Inc. Reduces Stock Position in GSK plc (NYSE:GSK)

Cullen Frost Bankers Inc. trimmed its holdings in GSK plc (NYSE:GSK) by 22.8% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 319,703 shares of the pharmaceutical company’s stock after selling 94,436 shares during the period. Cullen Frost Bankers Inc.’s holdings in GSK were worth $10,812,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also bought and sold shares of the company. FMR LLC grew its position in shares of GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock valued at $1,185,885,000 after purchasing an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC boosted its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares during the period. Hotchkis & Wiley Capital Management LLC grew its holdings in GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock valued at $144,803,000 after buying an additional 833,080 shares in the last quarter. Miller Howard Investments Inc. NY bought a new stake in shares of GSK during the fourth quarter valued at about $23,366,000. Finally, Bridgewater Associates LP lifted its holdings in shares of GSK by 107.3% in the third quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock worth $39,483,000 after buying an additional 500,010 shares in the last quarter. Institutional investors own 15.74% of the company’s stock.

GSK Trading Up 1.3 %

NYSE GSK opened at $39.30 on Friday. The company has a quick ratio of 0.52, a current ratio of 0.78 and a debt-to-equity ratio of 1.12. The stock’s 50-day simple moving average is $35.35 and its two-hundred day simple moving average is $37.21. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.92. The company has a market capitalization of $81.46 billion, a price-to-earnings ratio of 24.72, a PEG ratio of 1.12 and a beta of 0.58.

GSK (NYSE:GSK) last announced its quarterly earnings data on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. Research analysts forecast that GSK plc will post 4.14 EPS for the current fiscal year.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be paid a $0.3932 dividend. This is a boost from GSK’s previous quarterly dividend of $0.39. The ex-dividend date is Friday, February 21st. This represents a $1.57 dividend on an annualized basis and a dividend yield of 4.00%. GSK’s dividend payout ratio is 98.74%.

Wall Street Analysts Forecast Growth

GSK has been the topic of a number of analyst reports. Morgan Stanley began coverage on shares of GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. StockNews.com raised shares of GSK from a “buy” rating to a “strong-buy” rating in a report on Friday, February 7th. Deutsche Bank Aktiengesellschaft lowered GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and decreased their target price for the stock from $53.00 to $39.50 in a research note on Tuesday, November 12th. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.